Immutep’s combination of its LAG-3 protein/MHC (major histocompatibility complex) Class II agonist eftilagimod alfa and Merck & Co.’s immuno-oncology blockbuster Keytruda (pembrolizumab) has shown impressive median overall survival (OS) of 17.6 months in Cohort B (31 evaluable patients) of the TACTI-003 (KEYNOTE-C34) Phase IIb trial.
The trial is evaluating the combo as a first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma patients with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?